Rebetol

This page contains recent news articles, when available, and an overview of Rebetol but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Rebetol (when available)

Pharmacology and use:
Ribavirin is an anti-viral drug active against a number of DNA and RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to it's resemblence to building blocks of the RNA molecules. The oral form is used in the treatment of hepatitis C, in combination with interferon drugs. The aerosol form is used to treat respiratory syncytial virus-related diseases in children. The primary serious adverse effect of ribavirin is hemolytic anemia, which may worsen preexisting cardiac disease. For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV)

Mechanism Of Action:
Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral). Guanylyltranserase inhibition stops the capping of mRNA . These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity.

News Articles on Ribavirin

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518 ...  -  ‎Nov 2, 2009‎
The study includes two treatment arms in which patients receive a 4-week lead-in of PEGINTRON and REBETOL prior to receiving narlaprevir 200 mg or 400 mg ... Reuters

Schering-Plough reports encouraging results from Phase IIa hepatitis study  -  ‎Nov 4, 2009‎
In the lead-in arms of the study, in which patients received a four-week lead-in of Pegintron and Rebetol followed by the addition of narlaprevir, ... Trading Markets (press release)

AASLD: Treating Before Transplant Cuts HCV Recurrence  -  ‎Nov 6, 2009‎
...a course of pegylated interferon and ribavirin (Rebetol) before liver transplant may help them avoid recurrence of infection, a researcher said here. ... MedPage Today

Vertex pitches hepatitis drug to key doctors  -  ‎Nov 1, 2009‎
Consalvo said his company markets a combination of two drugs, PegIntron and Rebetol, as interferon treatments for hepatitis C, competing with Swiss drug ... Boston Globe

Aurobindo Pharma pares early losses on US nod for generic drug  -  ‎Nov 11, 2009‎
Ribavirin tablet is the generic Copegus and Ribavirin Capsules is generic equivalent to Rebetol of Schering Corporation. Ribavirin tablets and capsules are ... India Infoline.com

AASLD: New Drug Boosts HCV Clearance  -  ‎Nov 3, 2009‎
...weeks of pegylated interferon-alfa-2b (PEGIntron) and ribavirin (Rebetol) in a Phase II trial, said Paul Kwo, MD, of Indiana University in Indianapolis. ... MedPage Today

US nod for generic drug boosts Aurobindo Pharma  -  ‎Nov 5, 2009‎
Ribavirin tablet is the generic Copegus and Ribavirin Capsules is generic equivalent to Rebetol of Schering Corporation. Ribavirin tablets and capsules are ... India Infoline.com

UPDATE 1-FDA concerns remain over new use for Schering drug  -  ‎Oct 30, 2009‎
WASHINGTON, Oct 30 (Reuters) - The US Food and Drug Administration has "outstanding concerns" about Schering-Plough Corp's (SGP. ... Reuters

Schering-Plough Reports Financial Results for 2009 Third Quarter  -  ‎Oct 22, 2009‎
NUVARING 131 118 11% 375 330 14% CLARITIN Rx 95 87 9% 323 326 (1%) AVELOX 70 65 7% 250 274 (9%) INTEGRILIN 74 84 (12%) 223 236 (5%) REBETOL 64 63 1% 197 ... Reuters

La tua opinione è importante  -  ‎Nov 11, 2009‎
...o Peg-IFN alfa2b (PegIntron®) e ribavirina (Rebetol®) nel trattamento di pazienti naive (mai trattati) con infezione cronica da HCV genotipo 1. ... Associazione EpaC Onlus

Blueberry leaves can fight hepatitis C  -  ‎Aug 7, 2009‎
...once a week injections of a drug called pegylated interferon alfa, in addition to the antiviral drug ribavirin (Rebetol), taken twice daily by mouth. eMaxHealth

Π�?οσά�?αξε, απογευματινές ώ�?ες χθες, στη θαλάσσια πε�?ιοχή ...  -  ‎Jul 13, 2009‎
29χ�?ονος, διότι β�?έθηκαν στην κατοχή του ακατέ�?γαστη ινδική κάνναβη μικτο�? βά�?ους 9,4 γ�?αμμά�?ια, καθώς και τ�?ιάντα έξι (36) χάπια REBETOL. Υπουργείο Εμπορικής Ναυτιλίας

HCV Combination Therapy Approved for Non-Responders  -  ‎Apr 17, 2009‎
Fulford India, has received approval for its Viraferonpeg, the pegylated interferon therapy in combination with Rebetol, for re-treating adult patients Hepatitis Central

Suresh Karne, MD, Ph.D  -  ‎Apr 7, 2009‎
3.0 ug/kg) in Combination with Ribavarin (Rebetol) Treatment of Chronic Hepatitis C Patients: Gastroenterology-Irritable Bowel Syndrome. WHNT

Schering-Plough Says FDA Approves Label Expansion for Pegintron ...  -  ‎Mar 11, 2009‎
According to the Kenilworth, New Jersey-based Company, the approval of expanded indication transforms Pegintron - Rebetol combination as the first and only RTT News

Schering-Plough withdraws Cylatron melanoma filing in EU  -  ‎Mar 17, 2009‎
Last week, SP noted that the US Food and Drug Administration has approved new labelling for Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin) Pharma Times

FDA Approves Peginterferon/Ribavirin Combo for Treatment ...  -  ‎Mar 11, 2009‎
...and ribavirin (Rebetol) combination therapy for treating chronic hepatitis C in patients aged 3 years and older with compensated liver disease. DG News

미FDA, '페긴트론''레베톨' �?�?��? 확대  -  ‎Mar 11, 2009‎
...�?�?-푸�?�우는 만성 C형 간염 치료제�?� '페긴트론(Pegintron)'과 '레베톨(Rebetol)'�?� �?�?��? 확대 조치를 FDA로 부터 받았다고 11�?� 발표했다. 메디게이트뉴스

Expertos apuestan por el re-tratamiento de los pacientes con ...  -  ‎Feb 25, 2009‎
...que una terapia combinada de PegIntron (peginterferón alfa-2b) e Rebetol (ribavirina) arroja unos resultados positivos en el 57 por ciento de los casos. elEconomista.es

C간염 치료�? ‘페진트론+리베톨’ 복합 처방 승�?�  -  ‎Mar 16, 2009‎
...진 호 기�? �?�?프�?�우는 FDA로부터 3세 �?��? 만성 C 간염 환�? 치료�? 페진트론(Pegintron: alfa-2b peginterferon)과 리베톨(Rebetol: ribavirin) 복합 투여 허가를 메디포뉴스

SCHREIE EINES CANNABIS GESUNDHEITSIRRLÄUFERS  -  ‎Mar 9, 2009‎
Was bleibt, ist das breite Nebenwirkungsspektrum der antiviralen Kombi-Medikation Ribavirin („Rebetol“): Schmerzen, Schwäche, Husten, Erschöpfungszustände, Hanf Journal

Schering-Plough completes enrollment in registration studies of ...  -  Feb 1, 2009
The HCV Respond-2 study evaluates 36- and 48-week regimens of boceprevir in combination with Pegintron and Rebetol at the same doses as described above Pharmaceutical Business Review

Schering-Plough Completes Enrollment of Boceprevir Registration ...  -  Jan 27, 2009
This represents a near doubling of the 38 percent SVR rate for patients in the control group receiving 48 weeks of PEGINTRON and REBETOL alone (n=104) (ITT) PR Newswire (press release),

EU body recommends Teva's generic hepatitis C drug  -  Jan 22, 2009
N) Rebetol. Rebetol is an anti-viral drug often given in combination interferon therapy. The European Medicines Agency said on Thursday it had adopted a Reuters

Committee For Medicinal Products For Human Use Summary Of Positive ...  -  Jan 23, 2009
Ribavirin Teva is a generic of Rebetol. Studies have demonstrated the satisfactory quality of Ribavirin Teva, and its bioequivalence with the reference PharmaLive.com (press release),

Hepatitis C and HIV  -  Jan 21, 2009
The usual treatment is a combination of two drugs called pegylated interferon(Pegasys, Pegintron) and ribavirin (Rebetol, Virazole). guardian.co.uk,

Schering-Plough Reports Financial Results for 2008 Fourth Quarter ...  -  Feb 3, 2009
8, 2008) Announced US approval of PEGINTRON and REBETOL combination therapy for use in previously untreated patients 3 years of age and older with chronic PR Newswire (press release),

New products: Rx, generic, OTC  -  Jan 29, 2009
Schering-Plough announced the FDA has granted marketing approval to Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin, USP) combination therapy for Modern Medicine,

FDA requires more data on Schering's Saphris  -  Jan 16, 2009
In December last year Schering-Plough received approval from the FDA to market the Pegintron and Rebetol combined therapy to treat chronic hepatitis C. Hays Pharma,

EU Panel Backs Synflorix Of GlaxoSmithKline For Immunization  -  Jan 22, 2009
...of hepatitis C. The reference product for Ribavirin Teva is Rebetol, which is already authorized in the European Union in the indication applied for. EasyBourse.com,

TEVA: FÅR EU-REKOMMENDATION OM GODKÄNNANDE HEPATIT C-PREPARAT  -  Jan 22, 2009
Ribavirin är den aktiva substansen i Schering-Ploughs originalpreparat Rebetol. Medivir utvecklar ett preparat som behandling av hepatit C, TMC435, Dagens Nyheter,

丙�?�?�市场10年增5�?抑制剂屡败屡战  -  Jan 20, 2009
...市场上销售的PEG-IFN包括了先�?�葆雅公�?�的PEG-Intron�?罗�?公�?�的Pegasys；利巴韦林包括了先�?�葆雅公�?�的Rebetol 慧�?�网,

Schering-Plough Announces FDA Approval of PEGINTRON(TM) and ...  -  Dec 12, 2008
REBETOL is available both as capsules and in an oral solution formulation specifically available for pediatric use. "With the FDA approval of PEGINTRON MarketWatch

Schering-Plough wins FDA approval for hepatitis combination therapy  -  Dec 15, 2008
Rebetol combination therapy for use in previously untreated patients three years of age and older with chronic hepatitis C. According to the company, Trading Markets (press release),

Market Report -- In Play (SGP)  -  Dec 12, 2008
Schering-Plough anounces FDA approval of PEGINTRON and REBETOL combination therapy for treating pediatric Hepatitis C Co announces the FDA has granted MSN Money

FDA approves use of combo for hepatitis C in children  -  Dec 15, 2008
Schering-Plough obtained FDA clearance to market a regimen that combines Rebetol -- an antiviral drug -- with Pegintron -- a bioengineered version of an SmartBrief,

FDA Approvals: Lusedra and Pegintron/Rebitol  -  Dec 20, 2008
On December 11, the FDA approved combination therapy with peginterferon alfa-2b and ribavirin (Pegintron/Rebetol; Schering-Plough Corp) for use in patients Medscape

Synta gets $15m from Glaxo on cancer drug  -  Dec 12, 2008
Schering-Plough said the FDA had approved sales of a treatment combining its antiviral pill, Rebetol, with its PEG-Intron, an advanced, Boston Globe,

FDA Approves PEG-IFN Alfa-2b/Ribavirin Combination Therapy for ...  -  Dec 12, 2008
...and ribavirin (Rebetol) combination therapy for use in previously untreated patients aged 3 years of age and older with chronic hepatitis C virus (HCV). DG News

Penn Traffic loses $5.6M  -  Dec 12, 2008
Schering-Plough said Friday that FDA had approved sales of a treatment combining its antiviral pill, Rebetol, with its PEG-Intron, an advanced, Wilkes Barre Times-Leader,

C형 간염 소아 '페그�?�트론' 치료 받�?� 수 있어  -  Dec 14, 2008
...�?�?-푸�?�우�?� 항바�?�러스제 '레베톨(Rebetol)'과 면역 단백질�?� '페그�?�트론(PEG-Intron)' 병용 요법�?� C형 간염 소아�?� 치료제로 사용�?�는 것�?� 승�?�했다고 FDA가 12 메디게�?�트뉴스,

美国FDA批准佩�?能�?��?�利巴韦林治疗儿童丙型�?炎  -  Dec 18, 2008
...和�?��?管�?�局(FDA)正�?批准佩�?能(�?�乙二醇干扰素-2b，英文缩写PEG IFN -2b)�?��?�REBETOL 三�?�?�康网,

Boceprevir Phase II Study Showed High Rate of Sustained Response ...  -  Nov 1, 2008
These results compared to a 38 percent SVR rate (SVR 12) for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT). MarketWatch

Schering-Plough reports positive interim results from Phase II ...  -  Nov 4, 2008
These results compared to a 38% SVR rate (SVR 12) for patients in the control group receiving 48-weeks of Pegintron and Rebetol alone. Trading Markets (press release),

Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks ...  -  Nov 3, 2008
...re-treatment with Pegasys and Copegus in 942 patients who had not responded to PegIntron(TM) (peginterferon alfa-2b) and Rebetol(R) (ribavirin). PR-CANADA.net (press release),

Alargar el tratamiento a 72 semanas se postula como una opción ...  -  Nov 4, 2008
...los que no habían respondido al menos durante 12 semanas con PegIntron (interferón pegilado alfa 2b) más una terapia combinada de Rebetol (ribavirina). acceso.com (Comunicado de prensa),

Schering-Plough Reports Financial Results for Third Quarter of 2008  -  21 Oct 2008
24% 232 191 22% ZEMURON c/ 72 - - 202 - - AVELOX 65 78 (17%) 274 269 2% REBETOL 63 60 5% 193 206 (6%) SUBUTEX / SUBOXONE 63 55 15% 178 163 10% REMERON PR Newswire (press release),

From the analyst's couch: Hepatitis C therapies  -  Oct 3, 2008
Marketed ribavirin includes Rebetol (Schering–Plough), Copegus (Roche) and various generic versions. The overall clinical success rate, referred to as Nature.com (subscription),

Top-Line Results of Boceprevir Phase II Study Showed High Rate of ...  -  Aug 4, 2008
...(1-3) Patients in the study who received 48-weeks of boceprevir in combination with PEGINTRON and REBETOL from the beginning of treatment (no P/R lead-in) CNNMoney.com (press release)

Schering-Plough Reports Positive Results From Phase II Hepatitis Study  -  Aug 5, 2008
Patients in the study who received 48-weeks of boceprevir in combination with Pegintron and Rebetol from the beginning of treatment (no P/R lead-in) RedOrbit,

Schering-Plough reports positive top-line results for hepatitis C ...  -  Aug 4, 2008
Patients in the study who received 48-weeks of boceprevir in combination with Pegintron and Rebetol from the beginning of treatment achieved 66% SVR rate at RTT News,

Health Winners & Losers: Elan  -  Aug 4, 2008
The company said that at 48 weeks, the sustained virologic response (SVR) rate in the boceprevir-combination arm, with patients taking pegintron and rebetol TheStreet.com

Schering-Plough Reports Financial Results for Second Quarter of 2008  -  Jul 21, 2008
212 - - CLARITIN RX 111 102 8% 239 214 11% INTEGRILIN 78 78 - 152 163 (7%) CAELYX 78 65 20% 152 127 20% REBETOL 70 74 (5%) 130 146 (11%) ZEMURON c/ 67 PR Newswire (press release),

Malattie ematologiche: ruolo della Ribavirina nelle infezioni da ...  -  Jul 30, 2008
I pazienti con grave immunodeficienza sono stati trattati con Ribavirina ( Rebetol ), Immunoglobulina per via endovenosa e Palivizumab ( Synagis ), mentre i XagenaSalute,

Vertex drops as rival's hepatitis drug advances  -  May 21, 2008
Both studies will combine boceprevir after four weeks of treatment with two of Schering-Plough's older drugs, Peg-Intron and Rebetol. In the larger trial, Forbes,

Schering-Plough to Initiate Two Phase III Hepatitis Studies  -  May 22, 2008
In both Phase III clinical studies, patients will receive four weeks of treatment with Pegintron and Rebetol prior to the addition of boceprevir. RedOrbit,

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis ...  -  May 15, 2008
The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a Earthtimes (press release),

Valeant to Lay Off Half Its Workforce  -  May 6, 2008
And Viramadine, a replacement drug for Valeant’s hepatitis-C treatment, ribavarin (marketed by Schering-Plough under the name Rebetol), seemed just around PharmExec.com,

Brand Names/Synonyms:
Rebetol is also known by the following brand names and/or synonyms:
Biopolymers; Copegus; DRG-0028; HSDB 6513; ICN 1229; ICN-1229; RBV; RIBAV; RTC; RTCA; RTP; Rebetol; Rebetron; Rebretron; Ribamide; Ribamidil; Ribamidyl; Ribasphere; Ribavirin; Ribavirin Capsules; Ribavirin Triphosphate; Ribavirin [Usan:Inn]; Ribavirin-Tp; Ribavirina [Inn-Spanish]; Ribavirine; Ribavirine [Inn-French]; Ribavirinum [Inn-Latin]; Tribavirin; Varazid; Vilona; Viramid; Virazid; Virazole; Virazole 5'-Triphosphate

Drug Category:
Rebetol is categorized under the following by the FDA: Antiviral; ATC:J05AB04

Dosage Forms:
Inhalation solution, Tablets

Absorption:
Ribavirin was rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averaged 64% (44%).

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-1,2,4-triazole-3-carboxamide

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.